Edition:
United States

Agios Pharmaceuticals Inc (AGIO.O)

AGIO.O on Nasdaq

54.56USD
10:35am EDT
Change (% chg)

$-0.33 (-0.60%)
Prev Close
$54.89
Open
$54.95
Day's High
$55.17
Day's Low
$53.90
Volume
47,855
Avg. Vol
592,497
52-wk High
$67.74
52-wk Low
$35.84

Select another date:

Tue, Aug 8 2017

BRIEF-Agios posts Q2 loss per share $1.78‍​

* Agios Pharmaceuticals Inc - ‍collaboration revenue was $11.3 million for quarter ended June 30, 2017, compared to $7.0 million for comparable period in 2016​

BRIEF-Agios Pharma says FDA approves Idhifa for treating relapsed/refractory Acute Myeloid Leukemia

* FDA grants approval of Idhifa, the first oral targeted therapy for adult patients with relapsed/refractory acute myeloid leukemia and an IDH2 mutation Source text for Eikon: Further company coverage:

FDA approves leukemia treatment developed by Celgene, Agios

Aug 1 The U.S. Food and Drug Administration (FDA) on Tuesday approved Celgene Corp and Agios Pharmaceuticals Inc's treatment for acute myeloid leukemia (AML) patients with a specific genetic mutation.

BRIEF-Agios appoints David Scadden to the board of directors

* Agios appoints David Scadden to the board of directors Source text for Eikon: Further company coverage:

BRIEF-Thermo Fisher Scientific signs development agreement with Agios Pharmaceuticals

* Thermo Fisher Scientific signs development agreement with Agios Pharmaceuticals for next-generation sequencing oncology companion diagnostic in cholangiocarcinoma

BRIEF-Agios Pharmaceuticals to present updated clinical data from PKR activator AG-348

* Agios Pharmaceuticals Inc says to present updated clinical data from PKR activator AG-348 at EHA Source text for Eikon: Further company coverage:

BRIEF-Agios Pharmaceuticals Inc Q1 net loss was $66.2 million

* Agios Pharmaceuticals Inc - net loss for quarter ended March 31, 2017 was $66.2 million, compared to a net loss of $23.2 million for quarter ended March 31, 2016

BRIEF-Agios announces closing of over-allotment option in public offering

* Agios announces closing of over-allotment option in public offering

BRIEF-Agios and Aurigene enter into license agreement for novel small molecules for cancer metabolism target

* Agios and aurigene enter into exclusive license agreement for novel small molecules for cancer metabolism target

BRIEF-Agios Pharmaceuticals announces MTAP pathway research program and collaboration agreement with Celgene

* Agios announces MTAP pathway research program as development program and development candidate under master research and collaboration agreement with Celgene

Select another date: